Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Up 16.7% in February

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRXGet Rating) was the recipient of a large increase in short interest in February. As of February 28th, there was short interest totalling 131,300 shares, an increase of 16.7% from the February 13th total of 112,500 shares. Based on an average trading volume of 175,700 shares, the short-interest ratio is currently 0.7 days. Currently, 6.8% of the company’s shares are sold short.

Salarius Pharmaceuticals Stock Performance

SLRX stock opened at $2.10 on Wednesday. The stock has a 50-day moving average price of $2.31 and a 200-day moving average price of $2.88. Salarius Pharmaceuticals has a 1-year low of $1.07 and a 1-year high of $11.10. The firm has a market cap of $4.79 million, a PE ratio of -0.15 and a beta of 0.91.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Salarius Pharmaceuticals stock. Renaissance Technologies LLC lifted its holdings in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRXGet Rating) by 17.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 634,261 shares of the company’s stock after acquiring an additional 96,200 shares during the period. Renaissance Technologies LLC owned approximately 28.25% of Salarius Pharmaceuticals worth $124,000 as of its most recent filing with the Securities and Exchange Commission.

Salarius Pharmaceuticals Company Profile

(Get Rating)

Salarius Pharmaceuticals, Inc is a clinical-stage oncology company. The firm focuses on the development of Salarius’ clinical pipeline, which targets rare, orphan cancers and cancers with a high unmet need. The company was founded in 2014 and is headquartered in Houston, TX.

Read More

Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with's FREE daily email newsletter.